CPHI Podcast Series: The ripple effects of nearshoring in pharma
In the most recent instalment of the CPHI Podcast Series, Digital Editor Lucy Chard is joined by Sandra Sánchez y Oldenhage, President and CEO of PharmAdvice, to discuss nearshoring and reshoring in the pharmaceutical industry, and the subsequent ripple effects.
Nearshoring in pharma has been a high priorty in the industry recently, with pharmaceutical companies recognising the importance of supply chain security and global access to medicine even more over the last couple of years, especially in light of recent global events.
Sandra is a 35-year life sciences executive with significant operational and international experience operating top ranked pharmaceutical companies mainly in Latin America, including Pfizer, Merck, Sharp & Dohme, and Novartis, and was successful in establishing operations for Amgen and Biogen in Mexico as President and GM.
Her entrepreneurial spirit has led her to form her own consulting firm (PharmAdvice), leveraging her extensive and in-depth experience in the commercial, regulatory, government affairs and access fields throughout Latin America. Her broad international experience has involved responsibility for regions such as Latin America, Canada, and some countries in Asia, successfully navigating through their complex changing market dynamics. She has been very successful at influencing regulatory and government environments through public policy and lobbying efforts.
Since 2006, and in the years that follow, renowned Mexican business magazine, CNN EXPANSION, has named her one of the top 50 most powerful businesswomen in the country, and as of 2014 by Forbes Magazine. She was named by Pharma Exec’s in the USA as one of 17 Emerging Pharma Leaders in 2015. She was also one of 21 global executives selected by the International Women’s Foundation to participate in their elite Fellows Program for 2008-2010.
Sandra has endless accolades to her name and it's incredible interesting to hear her thoughts in the following interview. Covering the wide ranging topic of nearshoring in pharma, Sandra touches on manufacturing and supply, the monopoly that some regions currently have in certain fields, the various advantages and challenges that affect both the countries and the pharma companies, as well as the impacts nearshoring has economically, through things such as trade, and importantly the social impact, in equitable access to medicine, demonstrating the real ripple effect nearshoring has.
To listen to the full interview, follow the link below.
Related News
-
News Updated: Samsung Biologics to manufacture Pfizer's biosimilars products
Samsung Biologics agrees to use their biocampus Plant 4 for the manufacture of a line of products from Pfizer. -
News Novartis agrees for copies to be made of cancer drug to reach poorer countries
Novartis signs agreement with MPP to have generics of it's leukemia drug made so that it can be more easily distributed to the world's poorer countries. -
News Thermo Fisher Scientific opens new steriles drug manufacturing site in Singapore
The life science service and instrument provider have opened their new Singapore-based steriles drug manufacturing facility with the goal of bringing increased development and manufacturing capabilities for critical medicines to the APAC region. -
News Digital-first experimental approach to optimise drug formulations
Merck and XtalPi Inc. collaborate on an AI-powered technology platform to predict the crystal morphologies of diabetic medication metformin HCl, validated by wet-lab experiments conducted with Merck’s expertise, in a ‘digital-first’ a... -
News Bora Pharmaceuticals partners with Celltrion to crack the APAC market
Bora Pharmaceuticals, the international cGMP CDMO producing specialised pharmaceutical products such as sterile and non-sterile ophthalmics and nasal sprays for clinical use, is partnering with Celltrion Asia Pacific, subsidiary of Celltrion Group Inc. -
News 2023 Lunar New Year Round-up: Biopharma in the APAC region
With the Lunar New Year ushering in celebrations for the pharmaceutical community around the world on Sunday January 22, 2023, we’ve rounded up some of the top CPHI Online articles and reports from the last year looking at pharmaceutical markets ... -
News CPHI Pharma Award Winners 2022: API Development – Tokuyama Corporation
In this series of interviews, we speak to the teams behind the winning concepts at CPHI Pharma Awards 2022, which was held at CPHI Frankfurt, across the categories from digital innovation to CEO of the year. -
News Moderna to buy OriCiro Genomics in USD $85 million deal
Pharmaceutical company Moderna acquires genomics services company OriCiro Genomics, based in Tokyo, Japan, to boost mRNA therapeutics development and manufacturing portfolio.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance